Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00895466 | Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 12 | Pepscan TherapeuticsINDUSTRY | 1 | May 8, 2009 | clinicaltrials |
| NCT00120939 | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | completed | Phase 1 | 25 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| 131-I-TM-601 Study in Adults With Solid Tumors |
| completed |
| Phase 1 |
| 60 |
| TransMolecularINDUSTRY |
| 1 |
| Mar 31, 2009 |
| clinicaltrials |
| NCT00695851 | Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. | completed | Phase 1 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 30, 2009 | clinicaltrials |
| NCT00122005 | GVAX in Advanced Prostate Cancer Patients Made Lymphopenic | unknown | Phase 1 / Phase 2 | 18 | Providence Health & ServicesOTHER | 1 | Feb 24, 2009 | clinicaltrials |
| NCT00108264 | Tumor RNA Transfected Dendritic Cell Vaccines | completed | Phase 1 | — | US Department of Veterans AffairsFED | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00559429 | Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer(Tax-Sam) | completed | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 17, 2008 | clinicaltrials |
| NCT00127465 | Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants | completed | Phase 1 / Phase 2 | 400 | University of PlymouthOTHER | 1 | Dec 11, 2008 | clinicaltrials |
| NCT00061035 | Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma | completed | Phase 1 | 18 | Cosmo BioscienceINDUSTRY | 1 | Aug 28, 2008 | clinicaltrials |
| NCT00338026 | A Phase I Study of ECO-4601 in Patients With Advanced Cancer | completed | Phase 1 | 26 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00406939 | Vector Delivery of the IL-12 Gene in Men With Prostate Cancer | completed | Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Jul 10, 2008 | clinicaltrials |
| NCT00087854 | Study of Individualized Amonafide to Treat Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 23, 2008 | clinicaltrials |
| NCT00001382 | A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001444 | A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00064610 | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 102 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00140348 | Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine | completed | Phase 1 / Phase 2 | 80 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00121095 | Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer | unknown | Phase 1 / Phase 2 | 69 | Cytogen CorporationINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00283829 | Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 30 | University of WashingtonOTHER | 1 | Nov 29, 2007 | clinicaltrials |
| NCT00215709 | Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer | completed | Phase 1 | 17 | Geriatric Oncology ConsortiumOTHER | 1 | Nov 19, 2007 | clinicaltrials |
| NCT00115635 | Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 60 | Herlev HospitalOTHER | 1 | Oct 2, 2007 | clinicaltrials |
| NCT00441571 | Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer(CYT-500) | unknown | Phase 1 | 30 | Cytogen CorporationINDUSTRY | 1 | Sep 10, 2007 | clinicaltrials |
| NCT00186108 | A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer | completed | Phase 1 | 23 | Stanford UniversityOTHER | 1 | Jul 25, 2007 | clinicaltrials |
| NCT00070837 | MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 46 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2007 | clinicaltrials |
| NCT00080041 | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors | completed | Phase 1 | 20 | Pharmacyclics LLC.INDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00052000 | A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer | completed | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 1, 2007 | clinicaltrials |
| NCT00132756 | Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Morton Plant Mease Health CareOTHER | 1 | Nov 8, 2006 | clinicaltrials |
| NCT00188383 | Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 132 | University Health Network, TorontoOTHER | 1 | Mar 14, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00140374 | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) | completed | Phase 1 / Phase 2 | 36 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140387 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) | completed | Phase 1 / Phase 2 | 20 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140400 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 50 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Cell GenesysINDUSTRY | 0 | Jun 28, 2005 | clinicaltrials |
| NCT00006430 | A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA | unknown | Phase 1 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated May 8, 2009source: clinicaltrials